[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"retained-products-of-conception\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:retained-products-of-conception":25},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,7,0,[8,40,68,97,118,142,168],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":13,"acronym":4,"eligibilityCriteria":14,"healthyVolunteers":15,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":23,"conditions":24,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":28,"lastUpdatePostDateStruct":29,"startDateStruct":32,"completionDateStruct":34,"leadSponsor":36,"locationsCount":39},"100625381","a-prospective-multicenter-observational-real-world-study-of-retained-products-of-conception-100625381",false,"NCT07421895","A Prospective Multicenter Observational Real-world Study of Retained Products of Conception","Inclusion Criteria:Clinical diagnosis of retained products of conception, and ultrasound indicated that the maximum diameter of the lesion ≥0.5cm.\n\nExclusion Criteria:1) There is active bleeding requiring immediate surgical intervention;2) combined with obvious infection;3) Combined with severe organ dysfunction, including coagulation dysfunction.",true,"FEMALE","18 Years","45 Years",{"count":20,"type":21},600,"ESTIMATED","OBSERVATIONAL","The purpose of this study is to explore the optimal treatment strategy for retained products of pregnancy. Compared with surgical treatment, prospectively observe whether drug-assisted expectant management until the right time for surgery reduce the occurrence of intrauterine adhesions, and thus protect fertility.",[25,26],"Retained Products of Conception","RPOC","RECRUITING","2026-02-11",{"date":30,"type":31},"2026-02-19","ACTUAL",{"date":33,"type":31},"2022-06-01",{"date":35,"type":21},"2032-12-31",{"name":37,"class":38},"The Third Xiangya Hospital of Central South University","OTHER",1,{"id":41,"slug":42,"hasResults":11,"nctId":43,"briefTitle":44,"officialTitle":45,"acronym":4,"eligibilityCriteria":46,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":47,"enrollmentInfo":48,"targetDuration":4,"studyType":50,"phases":51,"briefSummary":53,"conditions":54,"keywords":55,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":59,"lastUpdatePostDateStruct":60,"startDateStruct":62,"completionDateStruct":64,"leadSponsor":66,"locationsCount":39},"100600832","phase-4-intracervical-vasopressin-100600832","NCT07102615","Intracervical Vasopressin","Intracervical Vasopressin for Completion of Hysteroscopic Removal of Retained Products of Conception","Inclusion Criteria:\n\n* Women\n* Aged 18-51\n* Undergoing surgical management for retained products of conception, postpartum retained products of conception or 1st trimester missed or incomplete abortion\n\nExclusion Criteria:\n\n* Hemodynamic instability\n* Active hemorrhage- soaking pad\u002Fhour\n* Allergy to vasopressin\n* Concern for intrauterine arteriovenous malformation\n* Inability to consent","51 Years",{"count":49,"type":21},50,"INTERVENTIONAL",[52],"PHASE4","This randomized study looks at whether using a medicine injected into the cervix of the uterus (intracervical), called vasopressin, helps to achieve better removal of retained products of conception (RPOC). RPOC means that after a pregnancy has ended (through miscarriage, abortion, or delivery), some parts of the pregnancy tissue, usually from the placenta or fetus, have stayed in the uterus. A hysteroscopic removal of RPOC is one type of treatment. This is a surgical procedure where a doctor uses a small camera attached to a thin tube (called a hysteroscope) to look inside the uterus.\n\nThe main goal of the study is :\n\n• To add to the existing research through this study to see if the injection of intracervical vasopressin leads to improved completion rates of hysteroscopic management of RPOC.\n\nParticipants will:\n\n• would be randomized to receive either vasopressin intracervical injection or a placebo injection (non-active saline) during your procedure. Information from the procedure will be collected from the participant's medical record.",[25],[56,57,58],"retained products of conception","intracervical","hysteroscopy","2025-10-31",{"date":61,"type":31},"2025-11-04",{"date":63,"type":31},"2025-10-30",{"date":65,"type":21},"2026-12-01",{"name":67,"class":38},"Prisma Health-Upstate",{"id":69,"slug":70,"hasResults":11,"nctId":71,"briefTitle":72,"officialTitle":73,"acronym":4,"eligibilityCriteria":74,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":75,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":77,"conditions":78,"keywords":81,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":88,"lastUpdatePostDateStruct":89,"startDateStruct":91,"completionDateStruct":93,"leadSponsor":95,"locationsCount":39},"100604218","comparison-of-operative-hysteroscopy-performed-in-the-operating-room-versus-outpatient-settings-100604218","NCT07146659","Comparison of Operative Hysteroscopy Performed in the Operating Room Versus Outpatient Settings","Comparison of Operative Hysteroscopy Performed in the Operating Room Versus Outpatient Settings : A Prospective Observational Study","Inclusion Criteria:\n\n* Women aged ≥ 18 years\n\n  -⁃ Undergoing operative hysteroscopy for intrauterine pathology\n* Able to provid e informed non-opposition\n* French-speaking\n\nExclusion Criteria:\n\n* Patients with contraindications to hysteroscopy\n* Pregnancy\n* Inability to complete follow-up",{"count":76,"type":21},400,"This is an observational prospective monocentric study which aims to compare operative hysteroscopies performed in the operating room under general or loco-regional anesthesia and those performed outside the operating room (outpatient operative hysteroscopy). The primary outcome is the success rate of the procedure. Secondary outcomes include postoperative pain, patient satisfaction, complications, and time to return to work.",[79,80,25],"Fibroid Uterus","Polyp Uterus",[82,83,84,85,86,87],"Hysteroscopy","Operative hysteroscopy","Outpatient ambulatory","Patient satisfaction","Outpatient hysteroscopy","Complications","2025-08-21",{"date":90,"type":31},"2025-08-28",{"date":92,"type":31},"2025-07-01",{"date":94,"type":21},"2027-05-31",{"name":96,"class":38},"Centre Hospitalier Intercommunal Creteil",{"id":98,"slug":99,"hasResults":11,"nctId":100,"briefTitle":101,"officialTitle":101,"acronym":4,"eligibilityCriteria":102,"healthyVolunteers":11,"sex":16,"minAge":4,"maxAge":4,"enrollmentInfo":103,"targetDuration":4,"studyType":22,"phases":4,"briefSummary":105,"conditions":106,"keywords":4,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":39},"100582344","a-prospective-study-evaluating-the-impact-of-conservative-management-on-retained-products-of-conception-and-emv-100582344","NCT06862089","A Prospective Study Evaluating the Impact of Conservative Management on Retained Products of Conception and EMV","Inclusion Criteria:\n\n* Recent history of miscarriage or delivery (within the past 8 weeks)\n* Strong willingness to undergo conservative management\n* Hemodynamically stable\n* Signed informed consent form\n\nExclusion Criteria:\n\n* Heavy vaginal bleeding (requiring immediate surgical intervention)\n* Active pelvic or systemic infection (e.g., fever \\>38°C, elevated CRP\u002FWBC)\n* Severe dysfunction of vital organs (heart, liver, or kidney)\n* Known drug allergies or contraindications to proposed medications (e.g., misoprostol intolerance)\n* Suspected ectopic pregnancy or gestational trophoblastic disease (confirmed by ultrasound or β-hCG levels)\n* Placenta accreta spectrum disorders diagnosed during current pregnancy\n* History of uterine artery embolization",{"count":104,"type":21},120,"The goal of this observational study is to learn about the therapeutic effects of the conservative treatment approach on pepole with retained products of conception (RPOC) and Enhanced myometrial vascularity (EMV).\n\nThe main question it aims to answer is: Is it possible to achieve the natural resolution of RPOC by combining it with EMV through conservative treatment？ Participants will receive conservative treatment (such as mifepristone, GnRH-a, or expectant management) following the initial diagnosis of RPOC and EMV, and the therapeutic efficacy of the conservative approach will be assessed after the completion of two menstrual cycles.",[25,107,108],"Miscarriage","Conservative Management","2025-06-12",{"date":111,"type":31},"2025-06-15",{"date":113,"type":31},"2024-10-23",{"date":115,"type":21},"2026-12-30",{"name":117,"class":38},"Fu Xing Hospital, Capital Medical University",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":4,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":125,"targetDuration":4,"studyType":50,"phases":127,"briefSummary":129,"conditions":130,"keywords":131,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":134,"lastUpdatePostDateStruct":135,"startDateStruct":137,"completionDateStruct":139,"leadSponsor":141,"locationsCount":39},"100445794","the-efficacy-of-auto-cross-linked-hyaluronic-acid-gel-in-the-prevention-of-adhesion-reformation-after-hysteroscopic-resection-of-retained-products-of-conception-100445794","NCT05085067","The Efficacy of Auto-cross Linked Hyaluronic Acid Gel in the Prevention of Adhesion Reformation After Hysteroscopic Resection of Retained Products of Conception","The Efficacy of Auto-crosslinked Hyaluronic Acid Gel in the Prevention of Adhesion Reformation After Hysteroscopic Resection of Retained Products of Conception:a Randomized Controlled Trial","Inclusion Criteria:\n\n* Clinical diagnosis of retained products of conception\n* Written consent obtained\n\nExclusion Criteria:\n\n* Patients with severe complications of medicine and surgery\n* Acute or chronic genital tract inflammation\n* No understanding or approving the randomized controlled trial",{"count":126,"type":21},86,[128],"NA","Retained product of conception (RPOC) is defined by abnormal trophoblastic persistence or retained placenta inside the uterus cavity after a pregnancy independently of the outcome. Untreated RPOC can compromise future fertility. RPOC are generally treated surgically, either by repeated evacuation or by hysteroscopy, which exposes the uterus to additional potential trauma.The combination of trauma to the gravid uterine cavity, hypoestrogenic state at the time of the operation or immediately afterward and local infection is considered to be the pathogenic mechanism of intrauterine adhesions (IUA) , manifested clinically by menstrual abnormalities, infertility and recurrent pregnancy loss.To investigate the efficacy of auto-cross linked hyaluronic acid gel in the prevention of adhesion reformation after hysteroscopic resection of retained products of conception.\n\nAfter the completion of hysteroscopic resection of retained products of conception, patients will be randomized to one of the two groups by computer-generated numbers: \\[1\\] infusing auto-cross linked hyaluronic acid gel into intrauterine cavity in the experimental group; \\[2\\] no auto-cross linked hyaluronic acid gel into intrauterine cavity in the control group. Second and third look outpatient hysteroscopy will be performed 4 and 8 weeks after the initial surgery. The patients will be followed up about menstrual pattern at 3 months after the surgery.The patients will be followed up about pregancy outcome at 12 months after the surgery.",[25],[25,82,132,133],"Intrauterine adhesion","Auto-crossed-linked hyaluronic acid gel","2025-03-10",{"date":136,"type":31},"2025-03-12",{"date":138,"type":31},"2022-04-01",{"date":140,"type":21},"2025-05-30",{"name":117,"class":38},{"id":143,"slug":144,"hasResults":11,"nctId":145,"briefTitle":146,"officialTitle":147,"acronym":4,"eligibilityCriteria":148,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":149,"targetDuration":4,"studyType":50,"phases":151,"briefSummary":152,"conditions":153,"keywords":4,"overallStatus":157,"whyStopped":4,"lastUpdateSubmitDate":158,"lastUpdatePostDateStruct":159,"startDateStruct":161,"completionDateStruct":163,"leadSponsor":165,"locationsCount":4},"100563808","impact-of-different-saline-pressures-during-hysteroscopy-on-visibility-feasibility-and-patients-discomfort-100563808","NCT06620978","Impact of Different Saline Pressures During Hysteroscopy on Visibility, Feasibility and Patients' Discomfort","Operative Hysteroscopy Without Anaesthesia: Impact of Different Distention Medium Pressure (Using Normal Saline) on Visibility, Feasibility and Patients' Discomfort","Inclusion Criteria:\n\n1. Women age \\>18 years\n2. Willing to undergo operative hysteroscopy without anesthesia for\n\nThe following intrauterine findings:\n\nA. Endometrial polyps \\<1.5 cm B. Retained products of conception \\<1.5 cm C. Lysis of intrauterine adhesions D. Removal of retained intrauterine device\n\nExclusion Criteria:\n\n1. Contraindication for hysteroscopy including: suspected pregnancy, heavy concomitant vaginal bleeding, known genital tract malignancy, suspected concurrent genital tract infection.\n2. Unable to sign informed consent\n3. Unable to read\u002Fwrite Hebrew",{"count":150,"type":21},100,[128],"Hysteroscopy is a minimally invasive diagnostic and therapeutic procedure for various intrauterine conditions. It is performed with an optic device while entering liquid media to the uterus to allow visualization. Diagnostic procedures are often performed without anaesthesia (in the office setting) and operative procedures are performed either under general anaesthesia or without anaesthesia (in the office setting). It depends on the patients' characteristics and preferences, and surgical indications. 80%-100% of operative procedure without anesthesia can be successfully completed. The main reasons for inability to successfully complete operative hysteroscopy without anesthesia are patients' discomfort and limited visibility of the uterine cavity.\n\nIn the current study, the investigators will compare the use of two different pressure setting of the liquid media during operative hysteroscopy without anesthesia, with the aim of investigating the successful completion of the procedure and patient's discomfort, with the aim of determining the optimal pressure setting.",[154,25,155,156],"Endometrial Polyps","Lysis of Intrauterine Adhesions","Removal of Retained Intrauterine Device","NOT_YET_RECRUITING","2024-10-01",{"date":160,"type":31},"2024-10-02",{"date":162,"type":21},"2024-11-01",{"date":164,"type":21},"2025-12-31",{"name":166,"class":167},"Assaf-Harofeh Medical Center","OTHER_GOV",{"id":169,"slug":170,"hasResults":11,"nctId":171,"briefTitle":172,"officialTitle":172,"acronym":173,"eligibilityCriteria":174,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":175,"enrollmentInfo":176,"targetDuration":4,"studyType":50,"phases":178,"briefSummary":179,"conditions":180,"keywords":181,"overallStatus":27,"whyStopped":4,"lastUpdateSubmitDate":185,"lastUpdatePostDateStruct":186,"startDateStruct":188,"completionDateStruct":190,"leadSponsor":192,"locationsCount":39},"100424241","removal-of-intrauterine-retained-products-of-conception-rpoc-after-miscarriage-guided-by-hysteroscopy-trial-a-randomized-controlled-trial-100424241","NCT04804332","Removal of Intrauterine Retained Products of Conception (RPOC) After Miscarriage Guided by Hysteroscopy Trial. A Randomized Controlled Trial.","RIGHT","Inclusion Criteria:\n\n* Patients after first trimester miscarriage treated non-surgically with sonographic evidence for the presence of RPOC at follow-up visit after 6 weeks (± 1 week) who have an immediate future pregnancy wish and are willing to give informed consent.\n\nExclusion Criteria:\n\n* Women aged below 18 years\n* Women aged over 39 years\n* Women not wanting to achieve pregnancy within the first 6 months after non-surgical treatment for miscarriage\n* Women with a history of repeated miscarriage defined as 3 or more consecutive pregnancy losses before 20 weeks of pregnancy duration\n* Women with untreated and\u002For untreatable subfertility\n* Women presenting with severe uterine bleeding, defined as uterine bleeding that needs acute intervention on medical grounds\n* Women presenting with severe abdominal pain, defined as abdominal pain that needs acute intervention on medical grounds\n* Women with fever (\\> 38.5° Celsius) or sepsis requiring antibiotic treatment. For the definition of 'sepsis' we refer to the Third International Consensus definitions for Sepsis and Septic Shock (Singer 2016)\n* Women with a contraindication for (office) operative hysteroscopy\n* Women with a failed non-surgical management for miscarriage, as substantiated by the sonographic finding of an intact gestational sac still in situ\n* Women with a congenital uterine anomaly\n* Known cervical stenosis making safe uterine access impossible\n* Visual or pathological (e.g. on biopsy) evidence of malignancy","39 Years",{"count":177,"type":21},244,[128],"Rationale: Elective immediate dilation and curettage (D\\&C) for miscarriage is associated with the occurrence of intrauterine adhesions (IUA). IUAs may be associated with subsequent subfertility and premature birth. Recent studies have shown that in women with miscarriage, medical treatment (misoprostol\u002Fmifepristone) is an effective alternative for curettage. A problem with medication and expectant management is that after initial treatment, sonographic findings during follow-up frequently show incomplete evacuation of uterine retained products of conception (RPOC), which often lead to additional interventions or expectant time-consuming management limiting the benefits of medical treatment.\n\nObjective: To assess, in women with a wish for immediate future pregnancy and RPOC after non-surgical management of a miscarriage, as diagnosed with sonography, the effects of operative hysteroscopy versus expectant management.\n\nStudy design: Multicenter randomized clinical trial. Study population: Patients after non-surgical management of a miscarriage with sonographic evidence of RPOC at the follow-up visit 6 weeks after initial treatment and wish for immediate (within 6 months) future pregnancy.\n\nIntervention: operative hysteroscopy versus expectant management. Main study parameters\u002Fendpoints: The primary outcome is time to next pregnancy, as substantiated by a positive urinary or serum hCG test. Secondary outcomes are Quality of Life (QOL) scores assessed with the SF-36, HADS and EQ-5D-5L, the need for additional and\u002For unscheduled treatments and\u002For visits and complications. Furthermore, data on the course of pregnancy - including miscarriage, ectopic pregnancy and live birth - are documented in those women who have an ongoing pregnancy after randomization during the study follow up period. In addition, iMTA PCQ questionnaires and health-costs are measured in all patients to perform a cost-effectiveness analysis.\n\nA total of 244 (122 per arm) women will be sufficient to answer the questions on the primary endpoint.\n\nNature and extent of the burden and risks associated with participation, benefit and group relatedness: Women participating in the study will be asked to fill out questionnaires at baseline, 8 weeks and 6 months after randomization. We don not expect specific risks as a result of either the intervention or expectant management.",[25],[25,182,58,183,184],"placental remnants","expectant management","fertility","2024-05-13",{"date":187,"type":31},"2024-05-14",{"date":189,"type":31},"2021-07-12",{"date":191,"type":21},"2027-12-30",{"name":193,"class":38},"University Hospital, Ghent"]